Overview

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Status:
Recruiting

Trial end date:
2025-09-25

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.

Phase:

Phase 2

Details

Lead Sponsor:

Insmed Incorporated

Treatments:

Mometasone Furoate